Source: Pharmacy Times articles
Experts discuss their institution’s implementation of step-up dosing for bispecific antibodies and share their best practices.
Read More
Recent Content
- New horizons in our understanding of precursor multiple myeloma and early interception
- Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
- Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma
- Blood test may predict response to CAR T-cell therapy in relapsed multiple myeloma
- Ninlaro Combo Delays Post-Transplant Progression in Relapsed Myeloma
- Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells
- Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma
- Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
- Imaging aspects of maxillomandibular bone alterations in patients with multiple myeloma treated with bisphosphonates: A systematic review
- Outcomes in Randomized Controlled Trials of Therapeutic Interventions for Multiple Myeloma: a Systematic Review